FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy
Stopped early · Not applicable
Conditions studied: Lung Cancer
In brief
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 (\^18FDG) positron emission tomography (PET)/CT scans, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying \^18FDG PET/CT scans to see how well they predict response in patients undergoing chemotherapy for stage IIIB or stage IV non-small cell lung cancer.
Key facts
- Study ID
- NCT00424138
- Run by
- American College of Radiology Imaging Network
- People needed
- 96
- Starts
- 2007-03-30
- Expected to finish
- 2011-08-31
- Last updated by the study team
- 2018-10-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.